Among anti-PD-L1 drugs, atezolizumab (MPDL3280A) is an engineered IgG antibody, with a modified Fc domain that prevents antibody-dependent cell-mediated cytotoxicity, actually approved by FDA for second line treatment of NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.